ATE484596T1 - Mutantes herpes-simplex-virus und verwendung davon bei der behandlung von plattenepithelkarzinom - Google Patents

Mutantes herpes-simplex-virus und verwendung davon bei der behandlung von plattenepithelkarzinom

Info

Publication number
ATE484596T1
ATE484596T1 AT04798619T AT04798619T ATE484596T1 AT E484596 T1 ATE484596 T1 AT E484596T1 AT 04798619 T AT04798619 T AT 04798619T AT 04798619 T AT04798619 T AT 04798619T AT E484596 T1 ATE484596 T1 AT E484596T1
Authority
AT
Austria
Prior art keywords
herpes simplex
simplex virus
cell carcinoma
squamous cell
treatment
Prior art date
Application number
AT04798619T
Other languages
English (en)
Inventor
Susanne Moira Brown
Paul Dunn
Bhuvanesh Singh
Ian Ganly
Original Assignee
Crusade Lab Ltd
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crusade Lab Ltd, Sloan Kettering Inst Cancer filed Critical Crusade Lab Ltd
Priority claimed from PCT/GB2004/004908 external-priority patent/WO2005049846A2/en
Application granted granted Critical
Publication of ATE484596T1 publication Critical patent/ATE484596T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT04798619T 2003-11-17 2004-11-17 Mutantes herpes-simplex-virus und verwendung davon bei der behandlung von plattenepithelkarzinom ATE484596T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0326798.6A GB0326798D0 (en) 2003-11-17 2003-11-17 Methods for generating mutant virus
US54130804P 2004-02-03 2004-02-03
PCT/GB2004/004908 WO2005049846A2 (en) 2003-11-17 2004-11-17 Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer

Publications (1)

Publication Number Publication Date
ATE484596T1 true ATE484596T1 (de) 2010-10-15

Family

ID=29763982

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04798619T ATE484596T1 (de) 2003-11-17 2004-11-17 Mutantes herpes-simplex-virus und verwendung davon bei der behandlung von plattenepithelkarzinom
AT04798569T ATE433493T1 (de) 2003-11-17 2004-11-17 Für eine heterologe nitroreduktase kodierender onkolytischer herpes simplex virus

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04798569T ATE433493T1 (de) 2003-11-17 2004-11-17 Für eine heterologe nitroreduktase kodierender onkolytischer herpes simplex virus

Country Status (7)

Country Link
US (3) US7498161B2 (de)
EP (3) EP1685254B1 (de)
JP (1) JP2007511215A (de)
AT (2) ATE484596T1 (de)
DE (2) DE602004029608D1 (de)
GB (1) GB0326798D0 (de)
WO (2) WO2005049844A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
WO2007026146A1 (en) * 2005-08-30 2007-03-08 Crusade Laboratories Limited Treatment using herpes simplex virus
US20070003520A1 (en) 2003-11-17 2007-01-04 Brown Susanne M Mutant viruses
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
GB0409596D0 (en) * 2004-04-29 2004-06-02 Crusade Lab Ltd Novel herpes simplex viruses and uses thereof
US20120301506A1 (en) * 2010-11-23 2012-11-29 Xiaoliu Zhang Oncolytic Virus as an Inducer for Innate Antitumor Immunity
US8163292B2 (en) 2007-02-16 2012-04-24 Virttu Biologics Limited Herpes simplex viruses and methods of viral replication
US20090081639A1 (en) * 2007-05-31 2009-03-26 Phil Hill Assay for sensitivity to chemotherapeutic agents
GB0714578D0 (en) * 2007-07-26 2007-09-05 Crusade Lab Ltd Viruses
WO2010127361A1 (en) * 2009-05-01 2010-11-04 Vivebio, Llc Method of pooling and/or concentrating biological specimens for analysis
US20130202639A1 (en) * 2010-03-25 2013-08-08 Konstantin G. Kousoulas Synthetic Herpes Simplex Viruses for Treatment of Cancers
WO2012008860A2 (en) 2010-07-16 2012-01-19 Auckland Uniservices Limited Bacterial nitroreductase enzymes and methods relating thereto
US9447156B2 (en) 2011-05-17 2016-09-20 St. Jude Children's Research Hospital Methods and compositions for inhibiting neddylation of proteins
US8859256B2 (en) 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
EP2662117A1 (de) 2012-05-11 2013-11-13 Virttu Biologics Limited Herpes Simplex Virus zur Behandlung von Leberkrebs
WO2014055960A1 (en) 2012-10-05 2014-04-10 Genelux Corporation Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
EA201700181A1 (ru) 2014-10-14 2017-09-29 Галозим, Инк. Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
MA43552A (fr) 2016-04-15 2018-11-07 Alpine Immune Sciences Inc Protéines immunomodulatrices à variants de cd80 et leurs utilisations
IL313289A (en) 2016-04-15 2024-08-01 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
CA3032120A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
EP3872180A1 (de) 2016-10-20 2021-09-01 Alpine Immune Sciences, Inc. Sekretierbare variante immunmodulatorische proteine und manipulierte zelltherapie
JP2020501589A (ja) 2016-12-23 2020-01-23 ウイルツ・バイオロジクス・リミテッド がんの治療
AU2018219895C1 (en) 2017-02-09 2024-10-03 Indapta Therapeutics, Inc. Engineered Natural Killer (NK) cells and compositions and methods thereof
AU2018235835A1 (en) 2017-03-16 2019-09-05 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
AU2018236224B2 (en) 2017-03-16 2024-01-04 Alpine Immune Sciences, Inc. PD-L1 variant immunomodulatory proteins and uses thereof
IL268781B2 (en) 2017-03-16 2025-09-01 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
PT3697810T (pt) 2017-10-18 2026-02-19 Alpine Immune Sciences Inc Proteínas imunomoduladoras de ligandos icos variantes e composições e métodos relacionados
EP3735417A1 (de) 2018-01-03 2020-11-11 Alpine Immune Sciences, Inc. Immunmodulatorische multidomänenproteine und verfahren zu deren verwendung
CN110117577B (zh) * 2018-02-05 2023-10-24 中国科学院武汉物理与数学研究所 低毒单纯疱疹病毒系统及其构建方法和应用
EP3787680A4 (de) * 2018-05-01 2022-06-22 Albert Einstein College of Medicine Hsv-2-delta-gd-vakzine und verfahren zu ihrer herstellung und verwendung
JP7379385B2 (ja) 2018-06-04 2023-11-14 カリディ・バイオセラピューティクス・インコーポレイテッド ウイルス療法を増強するための細胞ベースの媒体
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
EP3844276A2 (de) 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Manipulierte immunstimulierende bakterienstämme und verwendungen davon
CA3177862A1 (en) 2018-11-06 2020-05-14 Calidi Biotherapeutics, Inc. Enhanced systems for cell-mediated oncolytic viral therapy
WO2020107002A2 (en) 2018-11-21 2020-05-28 Indapta Therapeutics, Inc. Methods for expansion of natural killer (nk) cell subset and related compositions and methods
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
KR20210135987A (ko) 2018-11-30 2021-11-16 알파인 이뮨 사이언시즈, 인코포레이티드 Cd86 변이체 면역조절 단백질 및 그의 용도
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
WO2020176809A1 (en) 2019-02-27 2020-09-03 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
JP2023523429A (ja) 2020-04-22 2023-06-05 インダプタ セラピューティクス インコーポレイテッド ナチュラルキラー（ｎｋ）細胞組成物およびそれを生成させるための方法
WO2022147481A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
LT7046B (lt) 2022-04-15 2024-02-12 Vilniaus Universitetas Hidrolazės ir jų panaudojimas

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965138A (en) 1985-09-06 1999-10-12 Syntro Corporation Recombinant chimeric virus and uses thereof
JP2538367B2 (ja) 1988-06-24 1996-09-25 ブリティッシュ・テクノロジー・グループ・リミテッド Ｆｏｗｌｐｏｘウィルスの非必須領域
GB9102126D0 (en) 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
DE69133333T2 (de) 1991-08-26 2004-07-29 Baxter Healthcare S.A. Ein intaktes FPV-tk-Gen enthaltender rekombinanter Virus der Vogelpocken
US5633158A (en) * 1991-10-23 1997-05-27 Cancer Research Campaign Technology Limited Bacterial nitroreductase for the reduction of CB 1954 and analogues thereof to a cytotoxic form
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
WO1995004139A1 (en) 1993-07-27 1995-02-09 The Wistar Institute Of Anatomy And Biology Modified dna virus vectors and uses therefor
AT403167B (de) * 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
EP0753581A1 (de) 1995-07-10 1997-01-15 Immuno Ag Verbesserte rekombinante eukaryotische zytoplasmatische Viren, Methode ihrer Herstellung und ihrer Verwendung als Impfstoffe
ZA966287B (en) 1995-07-27 1998-03-09 American Cyanamid Co Avirulent herpetic viruses useful as tumoricidal agents and vaccines.
EP0856062A2 (de) 1995-10-19 1998-08-05 St. Jude Children's Research Hospital Herpesvirus-vektoren und deren verwendung
US5998174A (en) 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
GB9801930D0 (en) * 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
US5922576A (en) * 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
WO1999055345A1 (en) 1998-04-30 1999-11-04 The General Hospital Corporation Combination viral-based and gene-based therapy of tumors
US6573090B1 (en) * 1998-12-09 2003-06-03 The General Hospital Corporation Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors
KR100701905B1 (ko) * 1999-08-31 2007-04-02 더 제너럴 호스피탈 코포레이션 헤르페스 감마 34.5 유전자 발현을 재표적화하는 세포특이적 및/또는 종양 특이적 프로모터
EP1111061A1 (de) * 1999-12-20 2001-06-27 Universite Libre De Bruxelles Vektor mit doppelter Selektion
GB9930418D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
CN1250732C (zh) * 2000-01-21 2006-04-12 拜奥维克斯有限公司 病毒株
WO2003008573A2 (en) * 2001-07-17 2003-01-30 Anne Josephine Milner Silencing of gene expression by sirna
EP1419241A2 (de) 2001-08-21 2004-05-19 ML Laboratories PLC Verbesserte nitroreductase-enzyme
US7348418B2 (en) 2002-02-08 2008-03-25 Memorial Sloan-Kettering Cancer Center Carcinoma-related genes and polypeptides and methods of use thereof
GB0203285D0 (en) * 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
JP2005519091A (ja) * 2002-03-01 2005-06-30 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 癌の再発及び転移の予防
US7288529B2 (en) * 2003-04-24 2007-10-30 New York University ALK protein tyrosine kinase, cells and methods embodying and using same

Also Published As

Publication number Publication date
WO2005049844A3 (en) 2005-10-20
WO2005049845A9 (en) 2006-08-17
EP2281897A3 (de) 2011-11-30
WO2005049844A2 (en) 2005-06-02
US7498161B2 (en) 2009-03-03
DE602004021496D1 (de) 2009-07-23
EP1692294A2 (de) 2006-08-23
EP1685254B1 (de) 2009-06-10
EP1685254A2 (de) 2006-08-02
GB0326798D0 (en) 2003-12-24
WO2005049845A2 (en) 2005-06-02
US20070110720A1 (en) 2007-05-17
JP2007511215A (ja) 2007-05-10
ATE433493T1 (de) 2009-06-15
WO2005049845A3 (en) 2005-10-27
DE602004029608D1 (de) 2010-11-25
US20090208460A1 (en) 2009-08-20
US20070098689A1 (en) 2007-05-03
EP2281897A2 (de) 2011-02-09

Similar Documents

Publication Publication Date Title
ATE484596T1 (de) Mutantes herpes-simplex-virus und verwendung davon bei der behandlung von plattenepithelkarzinom
WO2005049846A3 (en) Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
DE60144517D1 (de) Rekombinante konstrukte und ihre verwendung bei der reduzierung der genexpression
AU2002327412A1 (en) Methods and compositions relating to improved lentiviral vector production systems
ATE513910T1 (de) Methoden zur gensuppression mithilfe von rnai verstärkenden faktoren
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
ATE513843T1 (de) Abstellen von genen in vivo durch chemischmodifizierte und stabile sirna
DK1554301T3 (da) Dengue-vaccine med en fælles udeladelse af 30 nukleotider i Dengue-typerne 1's og 2's3'UTR
HUP0300570A2 (hu) Cestrum sárga levélfodrosodás vírus promóterek
DK1309726T3 (da) RNA-sekvensspecifikke formidlere af RNA-interferens
DK1187852T3 (da) Ekspression og eksport af interferon-alpha-proteiner som Fc-fusionsproteiner
NO20074654L (no) Lenteviral-vektorer og deres anvendelse
Low et al. Structure and dynamics of the HIV-1 frameshift element RNA
AU2003261231A8 (en) Modified small interfering rna molecules and methods of use
PT95494A (pt) Processo para a producao de dna recombinante compreendendo sequencias derivadas de virus de rna, e manipulacoes geneticas que o utilizam
DE69434820D1 (de) Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis
WO2004058940A3 (en) Sirna-mediated gene silencing
Thormar A Comparison of Visna and Maedi Viruses: I.—Physical, Chemical and Biological Properties
ATE469984T1 (de) Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
Pelchat et al. Characterization of a viroid-derived RNA promoter for the DNA-dependent RNA polymerase from Escherichia coli
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
WO2005042719A3 (en) Methods for treating and preventing ischemia-reperfusion injury using rna interfering agents
ATE294866T1 (de) Zellen, die virus-resistent und von viren infizierbar sind
ATE365807T1 (de) Hepatitis b virus vektoren für gentherapie
DE69515652D1 (de) Verwendung von dna oligomeren zur hemmung von hiv durch reduktion ribosomaler leserasterverschichtung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties